Vaccines Market to Reach USD 93.08 billion by 2026, Approval For DENGVAXIA by USFDA to Spur Sales Opportunities, says Fortune Business Insights

NEXT STORY
MacroGenics Presents Results from the SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium
PREV STORY
BeyondSpring to Host Third-Quarter 2019 Financial Results and Operational Update Conference Call on December 18, 2019
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

AIT Therapeutics Reports Positive Top Line Results from its Nitric Oxide in Bronchiolitis (NO-BRO) Pilot Study in Infants

Pivotal study expected to commence in the fourth quarter of calendar year 2019 NEW ...

author_avatar
NASDAQ Market News

Summit Therapeutics Reports Financial Results for the Fiscal Year Ended 31 January 2018

author_avatar
NASDAQ Market News

Rhizen Pharmaceuticals S.A. and Curon Biopharmaceutical Limited Announce an Exclusive Licensing Agreement to Develop and Commercialize Tenalisib, a Dual PI3K Delta and Gamma Inhibitor for Oncology in Greater China

author_avatar
NASDAQ Market News